Registered Tanzania · TMDA

Flumesol-200 WS

Flumequine 200 mg/g

TZ 19 V 0018 Powder for Oral solution antiinfectives for systemic use INN generic

What it does

Flumequine is an antibiotic used to treat bacterial infections.

Commonly used for: bacterial infections, urinary tract infections, respiratory infections

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
TZ 19 V 0018
Registration date
2025-04-04
Expiry date
2030-04-02
Status
Registered/Compliant
Active ingredient
Flumequine 200 mg/g
Dosage form
Powder for Oral solution
Strength
-
Pack size
-
Therapeutic class
-
ATC class (WHO)
J01MB - Other quinolones
Drug group
ANTIINFECTIVES FOR SYSTEMIC USE
RxNorm RxCUI
25112
Manufacturer / MAH
Interchemie Werken ''De Adelaar'' B.v
Applicant / LTR
Interchemie Werken "De Adelaar" B.V
Country of origin
NETHERLANDS

Source: Tanzania Medicines and Medical Devices Authority · fetched 2026-07-30 03:00:40 · updated 2026-09-17 03:00:44

Disclaimer: This information is sourced from Tanzania Medicines and Medical Devices Authority (Tanzania). Always consult a qualified healthcare professional before using any medication.

About this medicine

Flumequine is an antibiotic used to treat bacterial infections.

What it treats

  • bacterial infections
  • urinary tract infections
  • respiratory infections

How it works

Flumequine works by stopping the growth of bacteria, helping the body fight off infections.

Who it's for

Flumequine is for people who have certain types of bacterial infections.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: flumequine

BNF-referenced

Flumequine is a fluoroquinolone antibiotic used primarily for the treatment of bacterial infections. It is effective against a variety of Gram-negative and some Gram-positive bacteria. The drug is particularly noted for its use in veterinary medicine but has applications in treating certain infections in humans as well. Flumequine's broad-spectrum activity makes it valuable in clinical settings where bacterial resistance to other antibiotics is a concern.

Indications

  • Urinary tract infections
  • Gastrointestinal infections
  • Respiratory infections
  • Skin and soft tissue infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients, as it varies with age and weight.

Adults: Refer to the BNF for specific dosing guidelines based on the type and severity of infection.

Mechanism of action

Flumequine exerts its antibacterial effects by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication, transcription, and repair. This inhibition leads to disruption of DNA supercoiling and ultimately results in bacterial cell death. The drug's action is concentration-dependent, meaning that higher drug concentrations lead to greater efficacy.

Pharmacodynamics

Flumequine demonstrates time-dependent killing, where the duration of exposure above the minimum inhibitory concentration (MIC) is important for its effectiveness. It has a broad spectrum of activity, particularly against enteric bacteria. Resistance may develop through mutations in DNA gyrase or topoisomerase IV or through efflux mechanisms in bacteria. The drug is typically bactericidal rather than bacteriostatic.

Pharmacokinetics

Flumequine is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It has a bioavailability of approximately 60-70%. The drug is widely distributed in body tissues and fluids, including lung, liver, and kidney. It is metabolized primarily in the liver, with a half-life of about 5 to 10 hours, and is excreted mainly via the kidneys. Renal impairment may affect the clearance of flumequine.

Pregnancy

Flumequine should not be used during pregnancy unless the potential benefits outweigh the risks, as safety in human pregnancy has not been established.

Breast-feeding

Flumequine is not recommended during breastfeeding as it is not known whether it is excreted in human milk.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

  • Tablets
  • Injectable solution
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: flumequine

PubChem CID 3374

Molecular formula: C14H12FNO3

Biological pathways

Gluconeogenesis WikiPathways

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.

Zambia 1 product